Quintet Private Bank Europe S.A. Sells 2,610 Shares of AbbVie Inc. $ABBV

Quintet Private Bank Europe S.A. reduced its position in AbbVie Inc. (NYSE:ABBV) by 41.2% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,721 shares of the company’s stock after selling 2,610 shares during the period. Quintet Private Bank Europe S.A.’s holdings in AbbVie were worth $862,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in ABBV. Vanguard Group Inc. raised its holdings in shares of AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares in the last quarter. Geode Capital Management LLC increased its holdings in AbbVie by 2.4% during the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after buying an additional 924,761 shares during the period. Charles Schwab Investment Management Inc. raised its stake in AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after buying an additional 1,517,222 shares in the last quarter. Norges Bank purchased a new stake in AbbVie during the second quarter worth $4,288,200,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in AbbVie by 5.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 12,771,854 shares of the company’s stock valued at $2,675,959,000 after acquiring an additional 713,148 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

Shares of AbbVie stock opened at $224.32 on Thursday. The firm has a market capitalization of $396.47 billion, a P/E ratio of 169.94, a PEG ratio of 1.27 and a beta of 0.36. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The company has a 50 day moving average price of $226.87 and a 200 day moving average price of $210.61. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is 496.97%.

Analysts Set New Price Targets

Several research firms have recently commented on ABBV. Raymond James Financial set a $256.00 price target on AbbVie in a research report on Monday, November 3rd. Morgan Stanley boosted their target price on shares of AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Scotiabank assumed coverage on shares of AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target on the stock. Bank of America lifted their price objective on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Finally, Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $245.84.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.